Related Experiment Videos
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment
P Mukherjee1, A R Ginardi, C S Madsen
1Department of Biochemistry and Molecular Biology, Mayo Clinic Scottsdale, Scottsdale, AZ 85259, USA.
Glycoconjugate Journal
|June 25, 2003
Summary
Pancreatic cancer immunotherapy shows promise, but tumor cells evade immune attack. Enhancing T cell responses and overcoming immune suppression in the tumor microenvironment are key for effective treatment.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Pancreatic cancer is a deadly disease with limited treatment options.
- Tumor-associated antigen MUC1 is over-expressed in most pancreatic adenocarcinomas and is a target for immunotherapy.
- A mouse model of pancreatic cancer exhibits tolerance to MUC1 and develops spontaneous tumors.
Purpose of the Study:
- To investigate if MUC1-based immunization can enhance anti-tumor immunity in pancreatic cancer.
- To understand the mechanisms of immune evasion employed by pancreatic tumors.
- To explore strategies for reversing T cell tolerance within the tumor microenvironment.
Main Methods:
- Utilized a clinically relevant mouse model of pancreatic cancer.
- Administered MUC1 peptide-based immunization to assess immune responses.
- Analyzed cytotoxic T cell (CTL) activity, cytokine secretion (IFN-gamma, IL-10, TGF-beta), and MHC class I expression.
- Investigated the role of anti-CD40 co-stimulation in reversing CTL tolerance.
- Identified CD4+ CD25+ T regulatory cells in the tumor microenvironment.
Main Results:
- MUC1 immunization generated mature, MUC1-specific CTLs that were cytotoxic to tumor cells in vitro.
- CTLs infiltrating the pancreatic tumor microenvironment became anergic and tolerized to MUC1.
- Pancreatic tumor cells secreted immunosuppressive cytokines (IL-10, TGF-beta) and down-regulated MHC class I.
- Anti-CD40 co-stimulation reversed CTL tolerance in vitro.
- Immune evasion mechanisms, including T regulatory cells, were identified in the tumor microenvironment.
Conclusions:
- MUC1-based immunization can induce a specific anti-tumor immune response but is ultimately hindered by tumor-induced immune tolerance.
- Pancreatic tumors employ multiple strategies to evade CTL killing, including cytokine secretion and MHC downregulation.
- Reversing CTL tolerance and modifying the tumor microenvironment are crucial for developing effective pancreatic cancer immunotherapies.